{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T02:13:26Z","timestamp":1773108806377,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s10637-023-01382-3","type":"journal-article","created":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T12:01:31Z","timestamp":1689422491000},"page":"629-637","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological assessment of the antineoplastic and immunomodulatory properties of a new spiroindolone derivative (7\u2019,8\u2019-Dimethoxy-1\u2019,3\u2019-dimethyl-1,2,3\u2019,4\u2019-tetrahydrospiro[indole-3,5\u2019-pyrazolo[3,4-c]isoquinolin]-2-one) in chronic myeloid leukemia"],"prefix":"10.1007","volume":"41","author":[{"given":"Carlos Eduardo","family":"de Castro Alves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge L.","family":"Bogza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Bohdan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander B.","family":"Rozhenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"de Freitas Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regiane Costa","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata Galv\u00e3o","family":"de Azevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larissa Raquel Silva","family":"Maciel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anamika","family":"Dhyani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andriy","family":"Grafov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemilson Soares","family":"Pontes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,15]]},"reference":[{"key":"1382_CR1","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","volume":"388","author":"H Wang","year":"2016","unstructured":"Wang H, Naghavi M, Allen C et al (2016) Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the global burden of Disease Study 2015. Lancet 388:1459. https:\/\/doi.org\/10.1016\/S0140-6736(16)31012-1","journal-title":"Lancet"},{"key":"1382_CR2","doi-asserted-by":"crossref","unstructured":"Campbell PJ, Martincorena I (2015) Somatic mutation in cancer and normal cells. Science (1979) 349:961\u2013968","DOI":"10.1126\/science.aab4082"},{"key":"1382_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"1382_CR4","doi-asserted-by":"publisher","unstructured":"Brown G (2022) Oncogenes and the Origins of Leukemias. Int J Mol Sci 23. https:\/\/doi.org\/10.3390\/IJMS23042293","DOI":"10.3390\/IJMS23042293"},{"key":"1382_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/CELLS10010117","volume":"10","author":"VR Minciacchi","year":"2021","unstructured":"Minciacchi VR, Kumar R, Krause DS (2021) Chronic myeloid leukemia: a model disease of the past, Present and Future. Cells 10:1\u201323. https:\/\/doi.org\/10.3390\/CELLS10010117","journal-title":"Cells"},{"key":"1382_CR6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.37545\/haematoljbd20177","volume":"13","author":"T Zhou","year":"2018","unstructured":"Zhou T, Medeiros JL, Hu S (2018) Chronic myeloid leukemia: beyond BCR-ABL1. Curr Hematol Malig Rep 13:435\u2013445. https:\/\/doi.org\/10.37545\/haematoljbd20177","journal-title":"Curr Hematol Malig Rep"},{"key":"1382_CR7","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/S12185-021-03126-6","volume":"113","author":"H Lee","year":"2021","unstructured":"Lee H, Basso IN, Kim DDH (2021) Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia. Int J Hematol 113:632\u2013641. https:\/\/doi.org\/10.1007\/S12185-021-03126-6","journal-title":"Int J Hematol"},{"key":"1382_CR8","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1038\/s41375-019-0562-1","volume":"33","author":"M Baccarani","year":"2019","unstructured":"Baccarani M, Rosti G, Soverini S (2019) Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type. Leukemia 33:2358\u20132364. https:\/\/doi.org\/10.1038\/s41375-019-0562-1","journal-title":"Leukemia"},{"key":"1382_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/2040620712468289","volume":"4","author":"PK Bhamidipati","year":"2013","unstructured":"Bhamidipati PK, Kantarjian H, Cortes J et al (2013) Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol 4:103\u2013117. https:\/\/doi.org\/10.1177\/2040620712468289","journal-title":"Ther Adv Hematol"},{"key":"1382_CR10","doi-asserted-by":"publisher","first-page":"101765","DOI":"10.1016\/J.TMAID.2020.101765","volume":"36","author":"SA Bouwman","year":"2020","unstructured":"Bouwman SA, Zoleko-Manego R, Renner KC et al (2020) The early preclinical and clinical development of cipargamin (KAE609), a novel antimalarial compound. Travel Med Infect Dis 36:101765. https:\/\/doi.org\/10.1016\/J.TMAID.2020.101765","journal-title":"Travel Med Infect Dis"},{"key":"1382_CR11","doi-asserted-by":"publisher","unstructured":"Altowyan MS, Barakat A, Al-Majid AM, Al-Ghulikah HA (2019) Spiroindolone Analogues as potential hypoglycemic with dual inhibitory activity on \u03b1-Amylase and \u03b1-Glucosidase. Molecules 24. https:\/\/doi.org\/10.3390\/MOLECULES24122342","DOI":"10.3390\/MOLECULES24122342"},{"key":"1382_CR12","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1016\/J.BMCL.2013.01.023","volume":"23","author":"Y Arun","year":"2013","unstructured":"Arun Y, Bhaskar G, Balachandran C et al (2013) Facile one-pot synthesis of novel dispirooxindole-pyrrolidine derivatives and their antimicrobial and anticancer activity against A549 human lung adenocarcinoma cancer cell line. Bioorg Med Chem Lett 23:1839\u20131845. https:\/\/doi.org\/10.1016\/J.BMCL.2013.01.023","journal-title":"Bioorg Med Chem Lett"},{"key":"1382_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/J.EJMECH.2008.03.013","volume":"44","author":"AS Girgis","year":"2009","unstructured":"Girgis AS (2009) Regioselective synthesis of dispiro[1H-indene-2,3\u2032-pyrrolidine-2\u2032,3\u2033-[3H]indole]-1,2\u2033(1\u2033H)-diones of potential anti-tumor properties. Eur J Med Chem 44:91\u2013100. https:\/\/doi.org\/10.1016\/J.EJMECH.2008.03.013","journal-title":"Eur J Med Chem"},{"key":"1382_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/S00044-008-9135-Y\/FIGURES\/1","volume":"18","author":"P Sharma","year":"2009","unstructured":"Sharma P, Kumar A, Sahu V et al (2009) Synthesis of bioactive spiro-2-[3\u2019-(2\u2019-phenyl)-3H-indolyl]-1-aryl-3- phenylaziridines and SAR studies on their antimicrobial behavior. Med Chem Res 18:383\u2013395. https:\/\/doi.org\/10.1007\/S00044-008-9135-Y\/FIGURES\/1","journal-title":"Med Chem Res"},{"key":"1382_CR15","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1021\/ACSINFECDIS.6B00041","volume":"2","author":"N Ye","year":"2016","unstructured":"Ye N, Chen H, Wold EA et al (2016) Therapeutic potential of Spirooxindoles as Antiviral Agents. ACS Infect Dis 2:382. https:\/\/doi.org\/10.1021\/ACSINFECDIS.6B00041","journal-title":"ACS Infect Dis"},{"key":"1382_CR16","first-page":"1","volume":"25","author":"RC de Oliveira","year":"2020","unstructured":"de Oliveira RC, Pontes GS, Kostyuk A et al (2020) Anticancer and immunomodulatory activities of a Novel Water-Soluble Derivative of Ellipticine. Biomolecules 25:1\u201312","journal-title":"Biomolecules"},{"key":"1382_CR17","doi-asserted-by":"publisher","unstructured":"Meyskens FL, Mukhtar H, Rock CL et al (2016) Cancer Prevention: obstacles, Challenges, and the Road ahead. JNCI J Natl Cancer Inst 108. https:\/\/doi.org\/10.1093\/JNCI\/DJV309","DOI":"10.1093\/JNCI\/DJV309"},{"key":"1382_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell JS, Teng MWL, Smyth MJ (2019) Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol 16:151\u2013167. https:\/\/doi.org\/10.1038\/s41571-018-0142-8","journal-title":"Nat Rev Clin Oncol"},{"key":"1382_CR19","unstructured":"LEAHY JW, LEWIS GL, NUSS JM et al (2005) ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE"},{"key":"1382_CR20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/J.BMCL.2015.12.086","volume":"26","author":"B Lu","year":"2016","unstructured":"Lu B, Cao H, Cao J et al (2016) Discovery of EBI-907: a highly potent and orally active B-Raf(V600E) inhibitor for the treatment of melanoma and associated cancers. Bioorg Med Chem Lett 26:819\u2013823. https:\/\/doi.org\/10.1016\/J.BMCL.2015.12.086","journal-title":"Bioorg Med Chem Lett"},{"key":"1382_CR21","doi-asserted-by":"publisher","unstructured":"Defois M, R\u00e9mondin C, Josselin B et al (2022) Synthesis and kinase inhibitory potencies of Pyrazolo[3,4-g]isoquinolines. Molecules 27. https:\/\/doi.org\/10.3390\/MOLECULES27175578","DOI":"10.3390\/MOLECULES27175578"},{"key":"1382_CR22","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/J.BCP.2010.01.007","volume":"79","author":"J Mortier","year":"2010","unstructured":"Mortier J, Frederick R, Ganeff C et al (2010) Pyrazolo[4,3-c]isoquinolines as potential inhibitors of NF-\u03baB activation. Biochem Pharmacol 79:1462\u20131472. https:\/\/doi.org\/10.1016\/J.BCP.2010.01.007","journal-title":"Biochem Pharmacol"},{"key":"1382_CR23","doi-asserted-by":"publisher","unstructured":"Theivendren P, Kunjiappan S, Hegde YM et al (2021) Importance of protein kinase and its inhibitor: a review. https:\/\/doi.org\/10.5772\/INTECHOPEN.98552","DOI":"10.5772\/INTECHOPEN.98552"},{"key":"1382_CR24","doi-asserted-by":"publisher","unstructured":"Boni C, Sorio C (2021) Current views on the interplay between Tyrosine Kinases and Phosphatases in Chronic myeloid leukemia. Cancers (Basel) 13. https:\/\/doi.org\/10.3390\/CANCERS13102311","DOI":"10.3390\/CANCERS13102311"},{"key":"1382_CR25","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613\/83554\/AM\/MOLECULAR-PATHWAYS-BCR-ABLBCR-ABL","volume":"18","author":"D Cilloni","year":"2012","unstructured":"Cilloni D, Saglio G (2012) Molecular pathways: BCR-ABL. Clin Cancer Res 18:930\u2013937. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1613\/83554\/AM\/MOLECULAR-PATHWAYS-BCR-ABLBCR-ABL.","journal-title":"Clin Cancer Res"},{"key":"1382_CR26","doi-asserted-by":"publisher","first-page":"15045","DOI":"10.1074\/JBC.271.25.15045","volume":"271","author":"LJ Thompson","year":"1996","unstructured":"Thompson LJ, Fields AP (1996) \u03b2II protein kinase C is required for the G2\/M phase transition of cell cycle. J Biol Chem 271:15045\u201315053. https:\/\/doi.org\/10.1074\/JBC.271.25.15045","journal-title":"J Biol Chem"},{"key":"1382_CR27","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1158\/1535-7163.MCT-09-0936","volume":"9","author":"K Wolanin","year":"2010","unstructured":"Wolanin K, Magalska A, Kusio-Kobialka M et al (2010) Expression of oncogenic kinase bcr-abl impairs mitotic checkpoint and promotes aberrant divisions and resistance to microtubule-targeting agents. Mol Cancer Ther 9:1328\u20131338. https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-0936","journal-title":"Mol Cancer Ther"},{"key":"1382_CR28","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1182\/BLOOD.V97.6.1823","volume":"97","author":"MA Morgan","year":"2001","unstructured":"Morgan MA, Dolp O, Reuter CWM (2001) Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1\/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood 97:1823\u20131834. https:\/\/doi.org\/10.1182\/BLOOD.V97.6.1823","journal-title":"Blood"},{"key":"1382_CR29","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1091\/MBC.E06-06-0530","volume":"18","author":"TN Feinstein","year":"2007","unstructured":"Feinstein TN, Linstedt AD (2007) Mitogen-activated protein kinase kinase 1-dependent golgi unlinking occurs in G2 phase and promotes the G2\/M cell cycle transition. Mol Biol Cell 18:594. https:\/\/doi.org\/10.1091\/MBC.E06-06-0530","journal-title":"Mol Biol Cell"},{"key":"1382_CR30","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.cyto.2016.08.032","volume":"89","author":"UM Raja","year":"2017","unstructured":"Raja UM, Gopal G, Shirley S et al (2017) Immunohistochemical expression and localization of cytokines\/chemokines\/growth factors in gastric cancer. Cytokine 89:82\u201390. https:\/\/doi.org\/10.1016\/j.cyto.2016.08.032","journal-title":"Cytokine"},{"key":"1382_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1042\/CS20110340","volume":"122","author":"M Mihara","year":"2012","unstructured":"Mihara M, Hashizume M, Yoshida H et al (2012) IL-6\/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 122:143\u2013159. https:\/\/doi.org\/10.1042\/CS20110340","journal-title":"Clin Sci (Lond)"},{"key":"1382_CR32","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/J.CCELL.2015.04.004","volume":"27","author":"RS Welner","year":"2015","unstructured":"Welner RS, Amabile G, Bararia D et al (2015) Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. Cancer Cell 27:671\u2013681. https:\/\/doi.org\/10.1016\/J.CCELL.2015.04.004","journal-title":"Cancer Cell"},{"key":"1382_CR33","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/J.CCR.2011.10.012","volume":"20","author":"D Reynaud","year":"2011","unstructured":"Reynaud D, Pietras E, Barry-Holson K et al (2011) IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 20:661. https:\/\/doi.org\/10.1016\/J.CCR.2011.10.012","journal-title":"Cancer Cell"},{"key":"1382_CR34","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1172\/JCI44952","volume":"121","author":"DT Fisher","year":"2011","unstructured":"Fisher DT, Chen Q, Skitzki JJ et al (2011) IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest 121:3846\u20133859. https:\/\/doi.org\/10.1172\/JCI44952","journal-title":"J Clin Invest"},{"key":"1382_CR35","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3109\/02656736.2013.807440","volume":"29","author":"ME Mikucki","year":"2013","unstructured":"Mikucki ME, Fisher DT, Ku AW et al (2013) Preconditioning thermal therapy: flipping the switch on IL-6 for anti-tumour immunity. Int J Hyperthermia 29:464\u2013473. https:\/\/doi.org\/10.3109\/02656736.2013.807440","journal-title":"Int J Hyperthermia"},{"key":"1382_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/CANCERS13020167","volume":"13","author":"B Mirlekar","year":"2021","unstructured":"Mirlekar B, Pylayeva-Gupta Y (2021) IL-12 family cytokines in Cancer and Immunotherapy. Cancers (Basel) 13:1\u201323. https:\/\/doi.org\/10.3390\/CANCERS13020167","journal-title":"Cancers (Basel)"},{"key":"1382_CR37","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/LEU.2011.239","volume":"26","author":"CIU Chen","year":"2012","unstructured":"Chen CIU, Koschmieder S, Kerstiens L et al (2012) NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. Leukemia 26:465\u2013474. https:\/\/doi.org\/10.1038\/LEU.2011.239","journal-title":"Leukemia"},{"key":"1382_CR38","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1002\/IJC.25233","volume":"127","author":"J Salih","year":"2010","unstructured":"Salih J, Hilpert J, Placke T et al (2010) The BCR\/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer 127:2119\u20132128. https:\/\/doi.org\/10.1002\/IJC.25233","journal-title":"Int J Cancer"},{"key":"1382_CR39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1590\/S1678-91992011000300009","volume":"17","author":"RA Harfoush","year":"2011","unstructured":"Nour el deen RAA, Harfoush RA, Elgharabawy MM et al (2011) Levels of interleukins 12 (IL-12) and 13 (IL-13), hepatitis B and C serology, and blood cultures among acute myeloid leukemia (AML) patients in Egypt. J Venom Anim Toxins including Trop Dis 17:293\u2013299. https:\/\/doi.org\/10.1590\/S1678-91992011000300009","journal-title":"J Venom Anim Toxins including Trop Dis"},{"key":"1382_CR40","doi-asserted-by":"publisher","first-page":"16074","DOI":"10.1038\/MTM.2016.74","volume":"3","author":"J Huang","year":"2016","unstructured":"Huang J, Liu Y, Au BC et al (2016) Preclinical validation: LV\/IL-12 transduction of patient leukemia cells for immunotherapy of AML. Mol Ther Methods Clin Dev 3:16074. https:\/\/doi.org\/10.1038\/MTM.2016.74","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01382-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-023-01382-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01382-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T11:02:58Z","timestamp":1696676578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-023-01382-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,15]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1382"],"URL":"https:\/\/doi.org\/10.1007\/s10637-023-01382-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,15]]},"assertion":[{"value":"9 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval for the utilization of human PBMCs was granted by the Research Ethics Committee (REC) of the Foundation of Hematology and Hemotherapy Foundation of Amazonas State (HEMOAM), Brazil (approval number: 3.138.343; approved on February 8, 2019).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors allowed the submission of the manuscript for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}